Generic competition · all medicines · read 12 November 2026
Is there a generic of Clindamycin Phosphate, and who makes it?
Clindamycin Phosphate appears in 10 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 22 generic makers listed as marketed across them. 3 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 2.6 and 13.1 years after the first brand approval. This is the Orange Book's listing, not a forecast.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.
- Clindamycin Phosphate appears in 10 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 22 generic makers listed as marketed across them.
- 3 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
- Where both are dated, the first generic approval came between 2.6 and 13.1 years after the first brand approval.
- Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.
Injectable, Injection
Four or more generic makers listed
Brand listed as marketed: Cleocin Phosphate and Clindamycin Phosphate In Dextrose 5%. 6 generic makers with 17 generic products listed as marketed; the first generic approval is dated 24 July 1987.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Pfizer Inc | 16 October 1987 | 1 |
| Hikma Pharmaceuticals Usa Inc | 25 April 1988 | 5 |
| Sagent Pharmaceuticals Inc | 30 September 2011 | 2 |
| Sandoz Inc | 31 May 2012 | 3 |
| Rising Pharma Holdings Inc | 4 April 2013 | 3 |
| Baxter Healthcare Corp | 28 June 2017 | 3 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Solution, Topical
Four or more generic makers listed
Every brand product here is listed as discontinued. 6 generic makers with 6 generic products listed as marketed; the first generic approval is dated 8 February 1982.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Padagis Us Llc | 30 November 1995 | 1 |
| Fougera Pharmaceuticals Inc | 5 June 1997 | 1 |
| Taro Pharmaceutical Industries Ltd | 31 March 2004 | 1 |
| Chartwell Rx Sciences Llc | 8 February 2018 | 1 |
| Zydus Lifesciences Ltd | 16 July 2018 | 1 |
| Encube Ethicals Pvt Ltd | 28 January 2019 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Gel, Topical
Four or more generic makers listed
Brand listed as marketed: Cleocin T and Clindagel. 11 generic makers with 11 generic products listed as marketed; the first generic approval is dated 28 January 2000.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Fougera Pharmaceuticals Inc | 28 January 2000 | 1 |
| Amvika Pharma Llc | 29 July 2020 | 1 |
| Sun Pharma Canada Inc | 10 November 2020 | 1 |
| Padagis Israel Pharmaceuticals Ltd | 31 December 2020 | 1 |
| Glenmark Pharmaceuticals Ltd | 10 February 2021 | 1 |
| Encube Ethicals Private Ltd | 11 March 2021 | 1 |
| Solaris Pharma Corp | 13 August 2021 | 1 |
| Amneal Pharmaceuticals Llc | 5 August 2022 | 1 |
| Zydus Lifesciences Ltd | 19 September 2023 | 1 |
| Alembic Pharmaceuticals Ltd | 2 April 2024 | 1 |
| Aurobindo Pharma Ltd | 18 March 2026 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Swab, Topical
Four or more generic makers listed
Every brand product here is listed as discontinued. 4 generic makers with 4 generic products listed as marketed; the first generic approval is dated 30 September 1996.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Padagis Us Llc | 25 May 2000 | 1 |
| Epic Pharma Llc | 17 June 2010 | 1 |
| Carnegie Pharmaceuticals Llc | 13 June 2025 | 1 |
| Rising Pharma Holdings Inc | 23 March 2026 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Lotion, Topical
Four or more generic makers listed
Brand listed as marketed: Cleocin T. 4 generic makers with 4 generic products listed as marketed; the first generic approval is dated 31 January 2002.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Fougera Pharmaceuticals Inc | 31 January 2002 | 1 |
| Padagis Israel Pharmaceuticals Ltd | 8 March 2021 | 1 |
| Sun Pharma Canada Inc | 28 June 2021 | 1 |
| Encube Ethicals Private Ltd | 18 January 2022 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Aerosol, Foam, Topical
One to three generic makers listed
Every brand product here is listed as discontinued. 3 generic makers with 3 generic products listed as marketed; the first generic approval is dated 31 March 2010.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Padagis Israel Pharmaceuticals Ltd | 31 March 2010 | 1 |
| Taro Pharmaceutical Industries Ltd | 11 March 2020 | 1 |
| Glenmark Pharmaceuticals Ltd | 20 September 2021 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Cream, Vaginal
One to three generic makers listed
Brand listed as marketed: Cleocin and Clindesse. 1 generic maker with 1 generic product listed as marketed; the first generic approval is dated 27 December 2004.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Fougera Pharmaceuticals Inc | 27 December 2004 | 1 |
Patents and exclusivities still listed
- 2 December 2026Patent 9789057 drug product
Solution, Intravenous
Brand listed, no generic listed as marketed
Brand listed as marketed: Clindamycin Phosphate In 0.9% Sodium Chloride. No generic is listed as marketed.
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Gel, Vaginal
Brand listed, no generic listed as marketed
Brand listed as marketed: Xaciato. No generic is listed as marketed.
Patents and exclusivities still listed
- 7 December 2029Exclusivity GAIN Xaciato
- 22 September 2036Patent 11129896
- 22 September 2036Patent 12303563 drug product
Suppository, Vaginal
Brand listed, no generic listed as marketed
Brand listed as marketed: Cleocin. No generic is listed as marketed.
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.
Where can you go from this result?
Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.